BR112016023397A2 - - Google Patents
Info
- Publication number
- BR112016023397A2 BR112016023397A2 BR112016023397A BR112016023397A BR112016023397A2 BR 112016023397 A2 BR112016023397 A2 BR 112016023397A2 BR 112016023397 A BR112016023397 A BR 112016023397A BR 112016023397 A BR112016023397 A BR 112016023397A BR 112016023397 A2 BR112016023397 A2 BR 112016023397A2
- Authority
- BR
- Brazil
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410144173.0 | 2014-04-10 | ||
| CN201410144173.0A CN104974161B (zh) | 2014-04-10 | 2014-04-10 | 作为PARP抑制剂的4H-吡唑并[1,5-α]苯并咪唑化合物的类似物 |
| CN201510113090 | 2015-03-13 | ||
| CN201510113090.X | 2015-03-13 | ||
| PCT/CN2015/075363 WO2015154630A1 (zh) | 2014-04-10 | 2015-03-30 | 作为PARP抑制剂的4H-吡唑并[1,5-α]苯并咪唑化合物的类似物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112016023397A2 true BR112016023397A2 (pt-PT) | 2017-08-15 |
| BR112016023397B1 BR112016023397B1 (pt) | 2022-08-16 |
Family
ID=54287319
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112016023397-2A BR112016023397B1 (pt) | 2014-04-10 | 2015-03-30 | Composto da fórmula ou um sal farmaceuticamente aceitável |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US9856262B2 (pt-PT) |
| EP (1) | EP3130592B1 (pt-PT) |
| JP (1) | JP6359175B2 (pt-PT) |
| KR (1) | KR101921486B1 (pt-PT) |
| CN (1) | CN106459057B (pt-PT) |
| AU (1) | AU2015245786B2 (pt-PT) |
| BR (1) | BR112016023397B1 (pt-PT) |
| CA (1) | CA2944801C (pt-PT) |
| DK (1) | DK3130592T3 (pt-PT) |
| ES (1) | ES2754590T3 (pt-PT) |
| HU (1) | HUE047410T2 (pt-PT) |
| IL (1) | IL248258B (pt-PT) |
| MX (1) | MX368496B (pt-PT) |
| NZ (1) | NZ725165A (pt-PT) |
| PL (1) | PL3130592T3 (pt-PT) |
| PT (1) | PT3130592T (pt-PT) |
| RU (1) | RU2672722C2 (pt-PT) |
| SA (1) | SA516380051B1 (pt-PT) |
| SG (1) | SG11201608438YA (pt-PT) |
| TW (1) | TWI671301B (pt-PT) |
| WO (1) | WO2015154630A1 (pt-PT) |
| ZA (1) | ZA201607736B (pt-PT) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104974161B (zh) * | 2014-04-10 | 2019-11-01 | 湖北生物医药产业技术研究院有限公司 | 作为PARP抑制剂的4H-吡唑并[1,5-α]苯并咪唑化合物的类似物 |
| CN108137598B (zh) * | 2015-09-30 | 2021-02-12 | 湖北生物医药产业技术研究院有限公司 | 4H-吡唑并[1,5-α]苯并咪唑类化合物的盐型、晶型及其制备方法和中间体 |
| US10722484B2 (en) | 2016-03-09 | 2020-07-28 | K-Gen, Inc. | Methods of cancer treatment |
| AU2018257582B2 (en) | 2017-04-27 | 2022-06-16 | Bayer Animal Health Gmbh | New bicyclic pyrazole derivatives |
| CN115028641B (zh) * | 2022-07-19 | 2024-05-28 | 湖南大学 | 一种钴催化合成5,8-双官能团取代咪唑并[1,2-a]吡嗪类化合物的方法 |
| CN116969954B (zh) * | 2023-09-21 | 2023-11-28 | 广东省农业科学院农业质量标准与监测技术研究所 | 一类含内酰胺的三环稠合杂环化合物及其应用 |
| CN117534677B (zh) * | 2024-01-09 | 2024-03-12 | 广东省农业科学院农业质量标准与监测技术研究所 | 一类含亚胺的三环稠合杂环化合物及其应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4916051A (en) * | 1987-04-07 | 1990-04-10 | Konica Corporation | Silver halide color photographic light-sensitive material |
| CA2550948A1 (en) * | 2003-12-22 | 2005-07-14 | Sb Pharmco Puerto Rico Inc. | Crf receptor antagonists and methods relating thereto |
| EP1973909A2 (en) * | 2005-12-22 | 2008-10-01 | Biogen Idec MA Inc. | Transforming growth factor modulators |
| WO2007144669A1 (en) * | 2006-06-15 | 2007-12-21 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Pyrazolo[1,5-a]quinazolin-5(4h)-ones as inhibitors of poly(adp-ribose)polymerase (parp) |
| MX2008016339A (es) * | 2006-06-20 | 2009-01-16 | Abbott Lab | Pirazoloquinazolinonas en la forma de inhibidores parp. |
| GB0701273D0 (en) * | 2007-01-24 | 2007-02-28 | Angeletti P Ist Richerche Bio | New compounds |
| ES2535511T3 (es) | 2012-04-26 | 2015-05-12 | Helmut Schickaneder | Ésteres de bendamustina y compuestos relacionados, y uso médico de los mismos |
| CA2872334C (en) | 2012-05-04 | 2020-06-30 | Dieter Dorsch | Pyrrolotriazinone derivatives |
| EP2666775A1 (en) * | 2012-05-21 | 2013-11-27 | Domain Therapeutics | Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors |
| AR091271A1 (es) | 2012-06-07 | 2015-01-21 | Hoffmann La Roche | Pirrolopirimidona y pirrolopiridona, inhibidores de tanquirasa |
| CA2877826C (en) * | 2012-07-09 | 2016-08-16 | Lupin Limited | Tetrahydroquinazolinone derivatives as parp inhibitors |
| CN103570725B (zh) | 2012-08-01 | 2017-03-22 | 中国科学院上海药物研究所 | 哌嗪并三唑类化合物及其制备方法和用途 |
| PL2882714T3 (pl) * | 2012-08-08 | 2020-02-28 | Merck Patent Gmbh | Pochodne (aza-)izochinolinonowe |
| CN104974161B (zh) | 2014-04-10 | 2019-11-01 | 湖北生物医药产业技术研究院有限公司 | 作为PARP抑制剂的4H-吡唑并[1,5-α]苯并咪唑化合物的类似物 |
-
2015
- 2015-03-30 AU AU2015245786A patent/AU2015245786B2/en active Active
- 2015-03-30 ES ES15777444T patent/ES2754590T3/es active Active
- 2015-03-30 WO PCT/CN2015/075363 patent/WO2015154630A1/zh active Application Filing
- 2015-03-30 SG SG11201608438YA patent/SG11201608438YA/en unknown
- 2015-03-30 EP EP15777444.9A patent/EP3130592B1/en active Active
- 2015-03-30 KR KR1020167031520A patent/KR101921486B1/ko active IP Right Grant
- 2015-03-30 NZ NZ725165A patent/NZ725165A/en unknown
- 2015-03-30 RU RU2016144202A patent/RU2672722C2/ru active
- 2015-03-30 PT PT157774449T patent/PT3130592T/pt unknown
- 2015-03-30 PL PL15777444T patent/PL3130592T3/pl unknown
- 2015-03-30 DK DK15777444T patent/DK3130592T3/da active
- 2015-03-30 MX MX2016013265A patent/MX368496B/es active IP Right Grant
- 2015-03-30 US US15/302,588 patent/US9856262B2/en active Active
- 2015-03-30 CA CA2944801A patent/CA2944801C/en active Active
- 2015-03-30 HU HUE15777444A patent/HUE047410T2/hu unknown
- 2015-03-30 JP JP2017504223A patent/JP6359175B2/ja active Active
- 2015-03-30 CN CN201580017657.1A patent/CN106459057B/zh active Active
- 2015-03-30 BR BR112016023397-2A patent/BR112016023397B1/pt active IP Right Grant
- 2015-04-08 TW TW104111236A patent/TWI671301B/zh active
-
2016
- 2016-10-09 IL IL248258A patent/IL248258B/en active IP Right Grant
- 2016-10-10 SA SA516380051A patent/SA516380051B1/ar unknown
- 2016-11-09 ZA ZA2016/07736A patent/ZA201607736B/en unknown
Also Published As
Similar Documents
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/03/2015, OBSERVADAS AS CONDICOES LEGAIS |